Osage University Partners Osage Partners Innovative Investment Funds for Changing Times Osage Venture Partners Investment Criteria The Entrepreneurs Hour Portfolio BA-Insight Canvas #0 (no title) Ceptaris CMC FieldView Solutions Halfpenny Technologies HardMetrics Identropy #0 (no title) InstaMed Medallion Analytics #0 (no title) Moda Technology Partners Pneuron ProtonMedia SevOne Team Robert Adelson Robert Adelson Bio Nate Lentz Nate Lentz Bio David Drahms David Drahms Bio Sean Dowling Sean Dowling Bio Claudia Dunnous Claudia Dunnous Bio News Archives 2010 Blog Careers Full-time Analyst Position Osage University Partners Fund Overview Investment Criteria Partner Universities Portfolio Aerie Pharmaceuticals Avid Radiopharmaceuticals Cleave Biosciences Corridor Pharmaceuticals Gevo, Inc. Immune Design Kolltan Pharmaceuticals, Inc. Liquid Light Luxtera, Inc. MC10, Inc. Sera Prognostics Skytree SolarBridge Technologies Tangent Medical Clinipace Worldwide Team Robert Adelson Robert Adelson Bio Marc Singer Marc Singer Bio Bill Harrington Bill Harrington Bio Louis Berneman Louis Berneman Bio Martin Lehr Martin Lehr Bio John Lee John Lee Bio Matthew Cohen Matthew Cohen Bio Bryce Istvan Bryce Istvan Bio Claudia Dunnous Claudia Dunnous Bio News Archives Research Contact Us Firm Overview Osage Connect Investment Criteria Partner Universities Portfolio Aerie Pharmaceuticals AGTC Algorithmia Ambiq Aptinyx Avid Radiopharmaceuticals Blade Body Labs Capella Bioscience Cardioxyl Cell Design Labs Clarifai Cleave Biosciences Clinipace Worldwide Corridor Pharmaceuticals Effector Enlibrium Evolv Faraday Gevo, Inc. Guardant Health Iconic Therapeutics Immune Design Infinio Jibo Kolltan Pharmaceuticals, Inc. Kura Kymeta Corp Liquid Light Luxtera, Inc. MC10, Inc. Menlo Security Merganser Millendo Mirna Otonomy Paracosm Picwell PMV Precision Biosciences Psikick Receptos Ribon Therapeutics Seismos Selecta Sera Prognostics Skytree SolarBridge Technologies Spero Therapeutics Streetlight Data Tangent Medical Urjanet Virdante Pharmaceuticals Voxel8 Team David Dorsey Bio Manny Stockman Manny Stockman Bio University Partners Team Robert Adelson Robert Adelson Bio Marc Singer Marc Singer Bio Bill Harrington Bill Harrington Bio Louis Berneman Louis Berneman Bio Kristen Albright Kristen Albright Bio Martin Lehr Martin Lehr Bio John Lee John Lee Bio Matthew Cohen Matthew Cohen Bio Bryce Istvan Claudia Dunnous Beth Grafstrom Claudia Dunnous Bio Beth Grafstrom Bio Britt Kennett Britt Kennett Bio David Dorsey Kirsten Leute Kirsten Leute Bio Stephanie Stehman Stephanie Stehman Bio News Archives Research Careers University Relations Manager Home | Osage University Partners Osage University Partners Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups that are commercializing university research. At OUP, we firmly believe that universities provide an unparalleled innovation engine to launch disruptive startups. Hence, we have partnered with over 70 of the most entrepreneurial universities and research centers to invest in their startups, and share part of our profits with those institutions to further promote the university entrepreneurial ecosystem. Our investment strategy is built on the following premises: Partner with passionate entrepreneurs and premier researchers who have disruptive technologies addressing large market opportunities Invest across all sectors of university commercialization, including Information Technology, Energy, Materials, and Life Science Invest across all stages of company development, seed through growth equity, with $5-10 million per investment Preference to syndicate with top-tier venture capital funds, but will lead in select circumstances Our singular focus on university startups, familiarity in working with technology transfer offices, $315 million in investment capital, and broad network uniquely position our fund as a preferred partner in university-originated startups. Recent News Blade Therapeutics Makes FierceBiotechs 2016 Fierce 15 List Infinio Accelerates Sales after Third Generation Product Release Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome Isolation Pioneer Menlo Security Receives US Patent for Adaptive Clientless Rendering (ACR) Celgene backs Cleave in $37M financing to tame protein homeostasis Taking it personally, cutting-edge biotech snags $45 million Follow OUP! Copyright © by Osage Partners. All rights reserved. SITE BY RADAR MEDIA